INTELLIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.22 USD | +0.19% |
|
+7.20% | -14.00% |
| May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
| May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Presentation Operator MessageOperator (Operator)Good morning and welcome to Intellia Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
26.22
USD
Average target price
70.26
USD
Spread / Average Target
+167.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.00% | 2.52B | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Transcript : Intellia Therapeutics, Inc. - Special Call